These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22080865)

  • 1. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.
    Curiel-Lewandrowski C; Yamasaki H; Si CP; Jin X; Zhang Y; Richmond J; Tuzova M; Wilson K; Sullivan B; Jones D; Ryzhenko N; Little F; Kupper TS; Center DM; Cruikshank WW
    J Clin Invest; 2011 Dec; 121(12):4838-49. PubMed ID: 22080865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription.
    Center DM; Cruikshank WW; Zhang Y
    J Immunol; 2004 Feb; 172(3):1654-60. PubMed ID: 14734747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
    Mehdi SJ; Moerman-Herzog A; Wong HK
    BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
    Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
    J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-IL-16 is associated with MHC class II-mediated negative regulation of mouse resting B cell activation through MAP kinases, NF-κB and Skp2-dependent p27kip regulation.
    Yang HY; Kim J; Kim SH; Choe CH; Jang YS
    Scand J Immunol; 2013 Mar; 77(3):177-86. PubMed ID: 23297678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
    Fivenson DP; Hanson CA; Nickoloff BJ
    J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 Regulates IL-4 Expression in TOX
    Huanosta-Murillo E; Alcántara-Hernández M; Hernández-Rico B; Victoria-Acosta G; Miranda-Cruz P; Domínguez-Gómez MA; Jurado-Santacruz F; Patiño-López G; Pérez-Koldenkova V; Palma-Guzmán A; Licona-Limón P; Fuentes-Pananá EM; Lemini-López A; Bonifaz LC
    Front Immunol; 2021; 12():668369. PubMed ID: 34220814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-IL-16 recruits histone deacetylase 3 to the Skp2 core promoter through interaction with transcription factor GABP.
    Zhang Y; Tuzova M; Xiao ZX; Cruikshank WW; Center DM
    J Immunol; 2008 Jan; 180(1):402-8. PubMed ID: 18097041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.
    Geskin LJ; Viragova S; Stolz DB; Fuschiotti P
    Blood; 2015 Apr; 125(18):2798-805. PubMed ID: 25628470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
    Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
    J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
    Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
    Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
    da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
    Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
    Huang Y; Su MW; Jiang X; Zhou Y
    Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas.
    Urosevic M; Willers J; Mueller B; Kempf W; Burg G; Dummer R
    Blood; 2002 Jan; 99(2):609-17. PubMed ID: 11781245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-IL-16 regulation in activated murine CD4+ lymphocytes.
    Ren F; Zhan X; Martens G; Lee J; Center D; Hanson SK; Kornfeld H
    J Immunol; 2005 Mar; 174(5):2738-45. PubMed ID: 15728482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
    Kohnken R; Wen J; Mundy-Bosse B; McConnell K; Keiter A; Grinshpun L; Hartlage A; Yano M; McNeil B; Chakravarti N; William B; Bradner JE; Caligiuri MA; Porcu P; Mishra A
    Blood; 2018 Feb; 131(7):771-781. PubMed ID: 29180399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL).
    Bunn PA; Foss FM
    J Cell Biochem Suppl; 1996; 24():12-23. PubMed ID: 8806090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.